Sharon Lynch is a Neurology physician affiliated with University of Kansas Medical Center. OpenAlex indexes 157 publications with 6,284 citations (h-index 45); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3901 Rainbow Blvd
4070 Delp Mail Stop 4017
Kansas City, KS 661600001
Telephone
913-588-6970Registry record last updated 8 Jul 2007.
Clinical trials
- Online Program to Reduce Depression in MS
Sponsor: Charite University, Berlin, Germany
- Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Sponsor: Vaccinex Inc.
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Sponsor: Acorda Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Vanda Pharmaceuticals Inc.Program year20253 payments
- Amgen Inc.Program year20253 payments
- Celgene CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
50.8%Gabapentinoids11.2%Gabapentin88%Pregabalin13%Part D≥109 patientsPotassium Channel Blocker7.4%Dalfampridine Er100%Part D≥51 patients+ 21 more classes in this area
Cancer & immunology
21.1%Pyrimidine Synthesis Inhibitor4.3%Teriflunomide62%Aubagio39%Part D≥20 patientsOther immunostimulants4%Copaxone47%Glatiramer Acetate28%Glatopa24%Part D<11 patients+ 8 more classes in this area
Musculoskeletal
17.5%gamma-Aminobutyric Acid-ergic Agonist12%Baclofen100%Part D≥157 patientsCentral alpha-2 Adrenergic Agonist4%Tizanidine Hcl100%Part D≥47 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2009 per NIH RePORTER. The latest:
- CLINICAL TRIAL: INTERFERON BETA-1A AND GLATIRAMIR IN MS
University of Kansas Medical Center
FY2009$78,047M01RR023940 - CLINICAL TRIAL: INTERFERON BETA-1A AND GLATIRAMIR IN MS
University of Kansas Medical Center
FY2008$70,392M01RR023940 - COMPARING THE USE INTERFERON BETA-1A & GLATIRAMIR ACETATE IN PATIENTS WITH MS
University of Kansas Medical Center
FY2007$37,953M01RR023940
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Mario Castro, MD
University of Kansas Medical Center
Jeffrey Burns, MD
University of Kansas Medical Center
Gary Gronseth, MD
University of Kansas Medical Center
Mazen Dimachkie, MD
University of Kansas Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”